Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach.

Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin. 72, 7–33 (2022).

pubmed: 35020204 doi: 10.3322/caac.21708

Webb, P. M. & Jordan, S. J. Global epidemiology of epithelial ovarian cancer. Nat. Rev. Clin. Oncol. 21, 389–400 (2024).

pubmed: 38548868 doi: 10.1038/s41571-024-00881-3

Lheureux, S., Gourley, C., Vergote, I. & Oza, A. M. Epithelial ovarian cancer. Lancet 393, 1240–1253 (2019).

pubmed: 30910306 doi: 10.1016/S0140-6736(18)32552-2

Clair, K. H., Wolford, J., Zell, J. A. & Bristow, R. E. Surgical management of gynecologic cancers. Surg. Oncol. Clin. N. Am. 30, 69–88 (2021).

pubmed: 33220810 doi: 10.1016/j.soc.2020.09.004

Ledermann, J. A. et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 29, iv259 (2018).

pubmed: 30285216 doi: 10.1093/annonc/mdy157

Coleridge, S. L., Bryant, A., Kehoe, S. & Morrison, J. Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst. Rev. 7, CD005343 (2021).

pubmed: 34328210

Moore, K. et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 379, 2495–2505 (2018).

pubmed: 30345884 doi: 10.1056/NEJMoa1810858

Perren, T. J. et al. A phase 3 trial of bevacizumab in ovarian cancer. N. Engl. J. Med. 365, 2484–2496 (2011).

pubmed: 22204725 doi: 10.1056/NEJMoa1103799

Ray-Coquard, I. et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N. Engl. J. Med. 381, 2416–2428 (2019).

pubmed: 31851799 doi: 10.1056/NEJMoa1911361

Narod, S. Can advanced-stage ovarian cancer be cured? Nat. Rev. Clin. Oncol. 13, 255–261 (2016).

pubmed: 26787282 doi: 10.1038/nrclinonc.2015.224

Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350–1355 (2018).

pubmed: 29567705 pmcid: 7391259 doi: 10.1126/science.aar4060

Makker, V. et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N. Engl. J. Med. 386, 437–448 (2022).

pubmed: 35045221 doi: 10.1056/NEJMoa2108330

Colombo, N. et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. N. Engl. J. Med. 385, 1856–1867 (2021).

pubmed: 34534429 doi: 10.1056/NEJMoa2112435

Cancer Genome Atlas Research Network Integrated genomic analyses of ovarian carcinoma. Nature 474, 609–615 (2011).

doi: 10.1038/nature10166

Konecny, G. E. et al. Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. J. Natl Cancer Inst. 106, dju249 (2014).

pubmed: 25269487 pmcid: 4271115 doi: 10.1093/jnci/dju249

Tothill, R. W. et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin. Cancer Res. 14, 5198–5208 (2008).

pubmed: 18698038 doi: 10.1158/1078-0432.CCR-08-0196

Zhang, L. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203–213 (2003).

pubmed: 12529460 doi: 10.1056/NEJMoa020177

Adams, S. F. et al. Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer. Cancer 115, 2891–2902 (2009).

pubmed: 19472394 doi: 10.1002/cncr.24317

Hao, J., Yu, H., Zhang, T., An, R. & Xue, Y. Prognostic impact of tumor-infiltrating lymphocytes in high grade serous ovarian cancer: a systematic review and meta-analysis. Ther. Adv. Med. Oncol. 12, 1758835920967241 (2020).

pubmed: 33193829 pmcid: 7607723 doi: 10.1177/1758835920967241

Ovarian Tumor Tissue Analysis, C. et al. Dose-response association of CD8

doi: 10.1001/jamaoncol.2017.3290

Sato, E. et al. Intraepithelial CD8

pubmed: 16344461 pmcid: 1311741 doi: 10.1073/pnas.0509182102

Bobisse, S. et al. Sensitive and frequent identification of high avidity neo-epitope specific CD8

pubmed: 29545564 pmcid: 5854609 doi: 10.1038/s41467-018-03301-0

Anadon, C. M. et al. Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T cells. Cancer Cell 40, 545–557.e13 (2022).

pubmed: 35427494 pmcid: 9096229 doi: 10.1016/j.ccell.2022.03.008

Duraiswamy, J. et al. Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation. Cancer Cell 39, 1623–1642.e20 (2021).

pubmed: 34739845 pmcid: 8861565 doi: 10.1016/j.ccell.2021.10.008

Strickland, K. C. et al. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget 7, 13587–13598 (2016).

pubmed: 26871470 pmcid: 4924663 doi: 10.18632/oncotarget.7277

Bruand, M. et al. Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING. Cell Rep. 36, 109412 (2021).

pubmed: 34289354 pmcid: 8371260 doi: 10.1016/j.celrep.2021.109412

Hamanishi, J. et al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J. Clin. Oncol. 33, 4015–4022 (2015).

pubmed: 26351349 doi: 10.1200/JCO.2015.62.3397

Hamanishi, J. et al. Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant ovarian cancer: open-label, randomized trial in Japan (NINJA). J. Clin. Oncol. 39, 3671–3681 (2021).

pubmed: 34473544 pmcid: 8601279 doi: 10.1200/JCO.21.00334

Varga, A. et al. Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: analysis of KEYNOTE-028. Gynecol. Oncol. 152, 243–250 (2019).

pubmed: 30522700 doi: 10.1016/j.ygyno.2018.11.017

Matulonis, U. A. et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann. Oncol. 30, 1080–1087 (2019).

pubmed: 31046082 doi: 10.1093/annonc/mdz135

Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455–2465 (2012).

pubmed: 22658128 pmcid: 3563263 doi: 10.1056/NEJMoa1200694

Liu, J. F. et al. Safety, clinical activity and biomarker assessments of atezolizumab from a phase I study in advanced/recurrent ovarian and uterine cancers. Gynecol. Oncol. 154, 314–322 (2019).

pubmed: 31204078 doi: 10.1016/j.ygyno.2019.05.021

Disis, M. L. et al. Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN solid tumor trial. JAMA Oncol. 5, 393–401 (2019).

pubmed: 30676622 pmcid: 6439837 doi: 10.1001/jamaoncol.2018.6258

Duraiswamy, J., Freeman, G. J. & Coukos, G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors – response. Cancer Res. 74, 633–634, discussion 635 (2014).

pubmed: 24408920 doi: 10.1158/0008-5472.CAN-13-2752

Hartl, C. A. et al. Combination therapy targeting both innate and adaptive immunity improves survival in a pre-clinical model of ovarian cancer. J. Immunother. Cancer 7, 199 (2019).

pubmed: 31362778 pmcid: 6668091 doi: 10.1186/s40425-019-0654-5

Pavicic, P. G. Jr et al. Immunotherapy with IL12 and PD1/CTLA4 inhibition is effective in advanced ovarian cancer and associates with reversal of myeloid cell-induced immunosuppression. Oncoimmunology 12, 2198185 (2023).

pubmed: 37066116 pmcid: 10101660 doi: 10.1080/2162402X.2023.2198185

Zamarin, D. et al. Randomized phase II trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer: an NRG oncology study. J. Clin. Oncol. 38, 1814–1823 (2020).

pubmed: 32275468 pmcid: 7255977 doi: 10.1200/JCO.19.02059

Leary, A. et al. Phase Ib INEOV neoadjuvant trial of the anti-PDL1, durvalumab (D) +/− anti-CTLA4 tremelimumab (T) with platinum chemotherapy for patients (pts) with unresectable ovarian cancer (OC): A GINECO study [abstract 727P]. Ann. Oncol. 32 (Suppl. 5), S731 (2021).

doi: 10.1016/j.annonc.2021.08.1170

Leary, A. et al. Phase Ib INEOV neoadjuvant trial of durvalumab +/− tremelimumab with platinum chemotherapy for patients (pts) with unresectable ovarian cancer (OC): Final complete resection and pathological response rates [abstract]. J. Clin. Oncol. 40 (Suppl. 16), 5557 (2022).

doi: 10.1200/JCO.2022.40.16_suppl.5557

Lo, C. S. et al. Neoadjuvant chemotherapy of ovarian cancer results in three patterns of tumor-infiltrating lymphocyte response with distinct implications for immunotherapy. Clin. Cancer Res. 23, 925–934 (2017).

pubmed: 27601594 doi: 10.1158/1078-0432.CCR-16-1433

Bohm, S. et al. Neoadjuvant chemotherapy modulates the immune microenvironment in metastases of tubo-ovarian high-grade serous carcinoma. Clin. Cancer Res. 22, 3025–3036 (2016).

pubmed: 27306793 doi: 10.1158/1078-0432.CCR-15-2657

Mesnage, S. J. L. et al. Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC). Ann. Oncol. 28, 651–657 (2017).

pubmed: 27864219 doi: 10.1093/annonc/mdw625

Kim, H. S. et al. Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer. Gynecol. Oncol. 151, 414–421 (2018).

pubmed: 30314669 doi: 10.1016/j.ygyno.2018.08.023

Jimenez-Sanchez, A. et al. Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy. Nat. Genet. 52, 582–593 (2020).

pubmed: 32483290 pmcid: 8353209 doi: 10.1038/s41588-020-0630-5

Peng, J. et al. Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-κB to foster an immunosuppressive tumor microenvironment in ovarian cancer. Cancer Res. 75, 5034–5045 (2015).

pubmed: 26573793 doi: 10.1158/0008-5472.CAN-14-3098

Ghaffari, A. et al. STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer. Br. J. Cancer 119, 440–449 (2018).

pubmed: 30046165 pmcid: 6133940 doi: 10.1038/s41416-018-0188-5

Liu, M. et al. Improved T-cell immunity following neoadjuvant chemotherapy in ovarian cancer. Clin. Cancer Res. 28, 3356–3366 (2022).

pubmed: 35443043 pmcid: 9357177 doi: 10.1158/1078-0432.CCR-21-2834

Zhang, Y. et al. Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer. Cancer Cell 39, 1578–1593.e8 (2021).

pubmed: 34653365 doi: 10.1016/j.ccell.2021.09.010

Socinski, M. A. et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N. Engl. J. Med. 378, 2288–2301 (2018).

pubmed: 29863955 doi: 10.1056/NEJMoa1716948

Sordo-Bahamonde, C. et al. Chemo-immunotherapy: a new trend in cancer treatment. Cancers 15(11), 2912 (2023).

pubmed: 37296876 pmcid: 10252089 doi: 10.3390/cancers15112912

Fucikova, J. et al. Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents. Trends Cancer 8, 426–444 (2022).

pubmed: 35181272 doi: 10.1016/j.trecan.2022.01.010

Monk, B. J. et al. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial. Lancet Oncol. 22, 1275–1289 (2021).

pubmed: 34363762 doi: 10.1016/S1470-2045(21)00342-9

Pujade-Lauraine, E. et al. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study. Lancet Oncol. 22, 1034–1046 (2021).

pubmed: 34143970 doi: 10.1016/S1470-2045(21)00216-3

Lee, E. K. et al. Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: a phase 2 clinical trial. Gynecol. Oncol. 159, 72–78 (2020).

pubmed: 32771276 doi: 10.1016/j.ygyno.2020.07.028

Moore, K. N. et al. Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III trial (IMagyn050/GOG 3015/ENGOT-OV39). J. Clin. Oncol. 39, 1842–1855 (2021).

pubmed: 33891472 pmcid: 8189598 doi: 10.1200/JCO.21.00306

Rahma, O. E. & Hodi, F. S. The intersection between tumor angiogenesis and immune suppression. Clin. Cancer Res. 25, 5449–5457 (2019).

pubmed: 30944124 doi: 10.1158/1078-0432.CCR-18-1543

Ruscito, I. et al. Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study). Br. J. Cancer 119, 330–338 (2018).

pubmed: 29955134 pmcid: 6070919 doi: 10.1038/s41416-018-0157-z

Leary, A., Tan, D. & Ledermann, J. Immune checkpoint inhibitors in ovarian cancer: where do we stand? Ther. Adv. Med. Oncol. 13, 17588359211039899 (2021).

pubmed: 34422119 pmcid: 8377306 doi: 10.1177/17588359211039899

Motz, G. T. & Coukos, G. The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat. Rev. Immunol. 11, 702–711 (2011).

pubmed: 21941296 doi: 10.1038/nri3064

Motz, G. T. et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat. Med. 20, 607–615 (2014).

pubmed: 24793239 pmcid: 4060245 doi: 10.1038/nm.3541

Liu, J. F. et al. Assessment of combined nivolumab and bevacizumab in relapsed ovarian cancer: a phase 2 clinical trial. JAMA Oncol. 5, 1731–1738 (2019).

pubmed: 31600397 pmcid: 6802049 doi: 10.1001/jamaoncol.2019.3343

Banerjee, S. et al. Principal results of the EORTC-1508 trial: a phase II randomised, multicentre study of bevacizumab vs atezolizumab and bevacizumab with acetylsalicylic acid or placebo in recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal adenocarcinoma [abstract LBA32]. Ann. Oncol. 32 (Suppl. 5), S1308 (2021).

doi: 10.1016/j.annonc.2021.08.2109

Kurtz, J. E. et al. Atezolizumab combined with bevacizumab and platinum-based therapy for platinum-sensitive ovarian cancer: placebo-controlled randomized phase III ATALANTE/ENGOT-ov29 trial. J. Clin. Oncol. 41, 4768–4778 (2023).

pubmed: 37643382 pmcid: 10602539 doi: 10.1200/JCO.23.00529

Lee, J. M. et al. Safety and clinical activity of the programmed death-ligand 1 inhibitor durvalumab in combination with poly (ADP-ribose) polymerase inhibitor olaparib or vascular endothelial growth factor receptor 1-3 inhibitor cediranib in women’s cancers: a dose-escalation, phase I study. J. Clin. Oncol. 35, 2193–2202 (2017).

pubmed: 28471727 pmcid: 5493052 doi: 10.1200/JCO.2016.72.1340

Le, D. T. & Jaffee, E. M. Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. Cancer Res. 72, 3439–3444 (2012).

pubmed: 22761338 pmcid: 3399042 doi: 10.1158/0008-5472.CAN-11-3912

Zsiros, E. et al. Efficacy and safety of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in the treatment of recurrent ovarian cancer: a phase 2 nonrandomized clinical trial. JAMA Oncol. 7, 78–85 (2021).

pubmed: 33211063 doi: 10.1001/jamaoncol.2020.5945

Ruscito, I. et al. Incorporating PARP-inhibitors in primary and recurrent ovarian cancer: a meta-analysis of 12 phase II/III randomized controlled trials. Cancer Treat. Rev. 87, 102040 (2020).

pubmed: 32485510 doi: 10.1016/j.ctrv.2020.102040

Ding, L. et al. PARP inhibition elicits STING-dependent antitumor immunity in Brca1-deficient ovarian cancer. Cell Rep. 25, 2972–2980.e5 (2018).

pubmed: 30540933 pmcid: 6366450 doi: 10.1016/j.celrep.2018.11.054

Shen, J. et al. PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness. Cancer Res. 79, 311–319 (2019).

pubmed: 30482774 doi: 10.1158/0008-5472.CAN-18-1003

Luo, X. et al. Poly(ADP-ribosyl)ation of FOXP3 protein mediated by PARP-1 protein regulates the function of regulatory T cells. J. Biol. Chem. 290, 28675–28682 (2015).

pubmed: 26429911 pmcid: 4661383 doi: 10.1074/jbc.M115.661611

Musacchio, L. et al. Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon? ESMO Open. 7, 100536 (2022).

pubmed: 35849879 pmcid: 9294238 doi: 10.1016/j.esmoop.2022.100536

Lee, E. K. & Konstantinopoulos, P. A. PARP inhibition and immune modulation: scientific rationale and perspectives for the treatment of gynecologic cancers. Ther. Adv. Med. Oncol. 12, 1758835920944116 (2020).

pubmed: 32782491 pmcid: 7383615 doi: 10.1177/1758835920944116

Drew, Y. et al. Olaparib plus durvalumab, with or without bevacizumab, as treatment in PARP inhibitor-naive platinum-sensitive relapsed ovarian cancer: a phase II multi-cohort study. Clin. Cancer Res. 30, 50–62 (2024).

pubmed: 37939124 doi: 10.1158/1078-0432.CCR-23-2249

Poveda, A. et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 22, 620–631 (2021).

pubmed: 33743851 doi: 10.1016/S1470-2045(21)00073-5

Konstantinopoulos, P. A. et al. Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. JAMA Oncol. 5, 1141–1149 (2019).

pubmed: 31194228 pmcid: 6567832 doi: 10.1001/jamaoncol.2019.1048

Farkkila, A. et al. Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. Nat. Commun. 11, 1459 (2020).

pubmed: 32193378 pmcid: 7081234 doi: 10.1038/s41467-020-15315-8

Capoluongo, E. D. et al. Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial. ESMO Open. 7, 100585 (2022).

pubmed: 36156447 pmcid: 9512829 doi: 10.1016/j.esmoop.2022.100585

Lampert, E. J. et al. Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase II study. Clin. Cancer Res. 26, 4268–4279 (2020).

pubmed: 32398324 pmcid: 7442720 doi: 10.1158/1078-0432.CCR-20-0056

González-Martin, A. et al. LBA37 - Atezolizumab (atezo) combined with platinum-based chemotherapy (CT) and maintenance niraparib for recurrent ovarian cancer (rOC) with a platinum-free interval (TFIp) >6 months: primary analysis of the double-blind placebo (pbo)-controlled ENGOT-Ov41/GEICO 69-O/ANITA phase III trial. Ann. Oncol. 34 (Suppl. 2), S1254–S1335 (2023).

Ledermann, J. A. et al. Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: exploratory analysis of KEYNOTE-100. Gynecol. Oncol. 178, 119–129 (2023).

pubmed: 37862791 doi: 10.1016/j.ygyno.2023.09.012

Drew, Y. et al. Phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): initial results in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC) [abstract 814MO]. Ann. Oncol. 31 (Suppl. 4), 615–616 (2020).

doi: 10.1016/j.annonc.2020.08.953

Banerjee, S. et al. Phase II study of olaparib plus durvalumab with or without bevacizumab (MEDIOLA): final analysis of overall survival in patients with non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancer [abstract 529MO]. Ann. Oncol. 33 (Suppl. 7), 788–789 (2022).

doi: 10.1016/j.annonc.2022.07.657

Kim, Y. N. et al. Triplet maintenance therapy of olaparib, pembrolizumab and bevacizumab in women with BRCA wild-type, platinum-sensitive recurrent ovarian cancer: the multicenter, single-arm phase II study OPEB-01/APGOT-OV4. Nat. Commun. 14, 5476 (2023).

pubmed: 37673858 pmcid: 10482952 doi: 10.1038/s41467-023-40829-2

Harter, P. et al. Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): results from the randomized, placebo (pbo)-controlled phase III DUO-O trial [abstract]. J. Clin. Oncol. 41 (Suppl. 17), LBA5506 (2023).

doi: 10.1200/JCO.2023.41.17_suppl.LBA5506

Freyer, G. et al. Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group. Nat. Commun. 15, 1985 (2024).

pubmed: 38443333 pmcid: 10914754 doi: 10.1038/s41467-024-45974-w

Cunnea, P. et al. Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC: implications for surgical and clinical outcomes. Cell Rep. Med. 4, 101055 (2023).

pubmed: 37220750 pmcid: 10313917 doi: 10.1016/j.xcrm.2023.101055

Prat, J. New insights into ovarian cancer pathology. Ann. Oncol. 23, X111–X117 (2012).

pubmed: 22987944 doi: 10.1093/annonc/mds300

Maxwell, M. B. et al. ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity. Cell 187, 3390–3408.e19 (2024).

pubmed: 38754421 doi: 10.1016/j.cell.2024.04.025

Norquist, B. M. et al. Inherited mutations in women with ovarian carcinoma. JAMA Oncol. 2, 482–490 (2016).

pubmed: 26720728 pmcid: 4845939 doi: 10.1001/jamaoncol.2015.5495

Sia, T. Y. et al. Treatment of ovarian clear cell carcinoma with immune checkpoint blockade: a case series. Int. J. Gynecol. Cancer 32, 1017–1024 (2022).

pubmed: 35545291 pmcid: 9356988 doi: 10.1136/ijgc-2022-003430

Xiao, X., Melton, D. W. & Gourley, C. Mismatch repair deficiency in ovarian cancer – molecular characteristics and clinical implications. Gynecol. Oncol. 132, 506–512 (2014).

pubmed: 24333356 doi: 10.1016/j.ygyno.2013.12.003

Fraune, C. et al. High homogeneity of MMR deficiency in ovarian cancer. Gynecol. Oncol. 156, 669–675 (2020).

pubmed: 31924330 doi: 10.1016/j.ygyno.2019.12.031

Friedman, C. F. et al. Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses. Nat. Med. 30, 1330–1338 (2024).

pubmed: 38653864 pmcid: 11108776 doi: 10.1038/s41591-024-02942-7

[No authors listed] World’s first TIL therapy approved. Nat. Biotechnol. 42, 349 (2024).

doi: 10.1038/s41587-024-02195-2

Baker, D. J., Arany, Z., Baur, J. A., Epstein, J. A. & June, C. H. CAR T therapy beyond cancer: the evolution of a living drug. Nature 619, 707–715 (2023).

pubmed: 37495877 doi: 10.1038/s41586-023-06243-w

Hong, D. S. et al. Autologous T cell therapy for MAGE-A4

pubmed: 36624315 pmcid: 9873554 doi: 10.1038/s41591-022-02128-z

Kawai, A. et al. Results from phase I/II study of NY-ESO-1-specific TCR gene-transduced T cell therapy (TBI-1301, mipetresgene autoleucel) in patients with advanced synovial sarcoma. J. Clin. Oncol. 41, 11558 (2023).

doi: 10.1200/JCO.2023.41.16_suppl.11558

Monberg, T. J., Borch, T. H., Svane, I. M. & Donia, M. TIL therapy: facts and hopes. Clin. Cancer Res. 29, 3275–3283 (2023).

pubmed: 37058256 doi: 10.1158/1078-0432.CCR-22-2428

Aoki, Y. et al. Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer. Cancer Res. 51, 1934–1939 (1991).

pubmed: 2004379

Fujita, K. et al. Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes. Clin. Cancer Res. 1, 501–507 (1995).

pubmed: 9816009

Pedersen, M. et al. Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study. Oncoimmunology 7, e1502905 (2018).

pubmed: 30524900 pmcid: 6279323 doi: 10.1080/2162402X.2018.1502905

Sarivalasis, A., Morotti, M., Mulvey, A., Imbimbo, M. & Coukos, G. Cell therapies in ovarian cancer. Ther. Adv. Med. Oncol. 13, 17588359211008399 (2021).

pubmed: 33995591 pmcid: 8072818 doi: 10.1177/17588359211008399

Verdegaal, E. M. E. et al. Timed adoptive T cell transfer during chemotherapy in patients with recurrent platinum-sensitive epithelial ovarian cancer. J. Immunother. Cancer 11, e007697 (2023).

pubmed: 37949617 pmcid: 10649798 doi: 10.1136/jitc-2023-007697

Morotti, M. et al. Promises and challenges of adoptive T-cell therapies for solid tumours. Br. J. Cancer 124, 1759–1776 (2021).

pubmed: 33782566 pmcid: 8144577 doi: 10.1038/s41416-021-01353-6

Gonzalez, T., Muminovic, M., Nano, O. & Vulfovich, M. Folate receptor alpha – a novel approach to cancer therapy. Int. J. Mol. Sci. 25, 1046 (2024).

pubmed: 38256120 pmcid: 11154542 doi: 10.3390/ijms25021046

Kershaw, M. H. et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12, 6106–6115 (2006).

pubmed: 17062687 pmcid: 2154351 doi: 10.1158/1078-0432.CCR-06-1183

Kandalaft, L. E., Powell, D. J. Jr & Coukos, G. A phase I clinical trial of adoptive transfer of folate receptor-α redirected autologous T cells for recurrent ovarian cancer. J. Transl. Med. 10, 157 (2012).

pubmed: 22863016 pmcid: 3439340 doi: 10.1186/1479-5876-10-157

Daigre, J. et al. Preclinical evaluation of novel folate receptor 1-directed CAR T cells for ovarian cancer. Cancers 16, 333 (2024).

pubmed: 38254822 pmcid: 10813853 doi: 10.3390/cancers16020333

Adusumilli, P. S. et al. A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab. Cancer Discov. 11, 2748–2763 (2021).

pubmed: 34266984 pmcid: 8563385 doi: 10.1158/2159-8290.CD-21-0407

Hassan, R. et al. Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results. Nat. Med. 29, 2099–2109 (2023).

pubmed: 37501016 pmcid: 10427427 doi: 10.1038/s41591-023-02452-y

Adusumilli, P. S. et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci. Transl. Med. 6, 261ra151 (2014).

pubmed: 25378643 pmcid: 4373413 doi: 10.1126/scitranslmed.3010162

Mackensen, A. et al. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nat. Med. 29, 2844–2853 (2023).

pubmed: 37872225 pmcid: 10667102 doi: 10.1038/s41591-023-02612-0

Wu, J. W. Y. et al. T-cell receptor therapy in the treatment of ovarian cancer: a mini review. Front. Immunol. 12, 672502 (2021).

pubmed: 33927729 pmcid: 8076633 doi: 10.3389/fimmu.2021.672502

Gitto, S. B., Ihewulezi, C. J. N. & Powell, D. J. Jr Adoptive T cell therapy for ovarian cancer. Gynecol. Oncol. 186, 77–84 (2024).

pubmed: 38603955 doi: 10.1016/j.ygyno.2024.04.001

D’Angelo, S. P. et al. Antitumor activity associated with prolonged persistence of adoptively transferred NY-ESO-1 (c259)T cells in synovial sarcoma. Cancer Discov. 8, 944–957 (2018).

pubmed: 29891538 pmcid: 8092079 doi: 10.1158/2159-8290.CD-17-1417

Robbins, P. F. et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29, 917–924 (2011).

pubmed: 21282551 pmcid: 3068063 doi: 10.1200/JCO.2010.32.2537

Dhodapkar, K. M., Krasovsky, J., Williamson, B. & Dhodapkar, M. V. Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J. Exp. Med. 195, 125–133 (2002).

pubmed: 11781371 pmcid: 2196013 doi: 10.1084/jem.20011097

Gnjatic, S. et al. NY-ESO-1: review of an immunogenic tumor antigen. Adv. Cancer Res. 95, 1–30 (2006).

pubmed: 16860654 doi: 10.1016/S0065-230X(06)95001-5

Matsuzaki, J. et al. Tumor-infiltrating NY-ESO-1-specific CD8

pubmed: 20385810 pmcid: 2867907 doi: 10.1073/pnas.1003345107

Yarza, R. et al. Efficacy of T-cell receptor-based adoptive cell therapy in cutaneous melanoma: a meta-analysis. Oncologist 28, e406–e415 (2023).

pubmed: 37036865 pmcid: 10243774 doi: 10.1093/oncolo/oyad078

Meeuwsen, M. H. et al. Broadly applicable TCR-based therapy for multiple myeloma targeting the immunoglobulin J chain. J. Hematol. Oncol. 16, 16 (2023).

pubmed: 36850001 pmcid: 9969645 doi: 10.1186/s13045-023-01408-6

Szender, J. B. et al. NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer. Gynecol. Oncol. 145, 420–425 (2017).

pubmed: 28392127 pmcid: 5497581 doi: 10.1016/j.ygyno.2017.03.509

Kandalaft, L. E., Dangaj Laniti, D. & Coukos, G. Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation. Nat. Rev. Cancer 22, 640–656 (2022).

pubmed: 36109621 doi: 10.1038/s41568-022-00503-z

Garsed, D. W. et al. The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer. Nat. Genet. 54, 1853–1864 (2022).

pubmed: 36456881 pmcid: 10478425 doi: 10.1038/s41588-022-01230-9

Larson, R. C. et al. Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma. Nat. Commun. 14, 7509 (2023).

pubmed: 37980341 pmcid: 10657357 doi: 10.1038/s41467-023-43416-7

Liu, Y. L. et al. BRCA mutations, homologous DNA repair deficiency, tumor mutational burden, and response to immune checkpoint inhibition in recurrent ovarian cancer. JCO Precis. Oncol. 4, https://doi.org/10.1200/PO.20.00069 (2020).

Doroshow, D. B. et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat. Rev. Clin. Oncol. 18, 345–362 (2021).

pubmed: 33580222 doi: 10.1038/s41571-021-00473-5

Parvathareddy, S. K. et al. Differential expression of PD-L1 between primary and metastatic epithelial ovarian cancer and its clinico-pathological correlation. Sci. Rep. 11, 3750 (2021).

pubmed: 33580098 pmcid: 7881132 doi: 10.1038/s41598-021-83276-z

Topalian, S. L., Taube, J. M., Anders, R. A. & Pardoll, D. M. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat. Rev. Cancer 16, 275–287 (2016).

pubmed: 27079802 pmcid: 5381938 doi: 10.1038/nrc.2016.36

Abiko, K., Hamanishi, J., Matsumura, N. & Mandai, M. Dynamic host immunity and PD-L1/PD-1 blockade efficacy: developments after “IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer”. Br. J. Cancer 128, 461–467 (2023).

pubmed: 36068276 doi: 10.1038/s41416-022-01960-x

Webb, J. R., Milne, K., Kroeger, D. R. & Nelson, B. H. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer. Gynecol. Oncol. 141, 293–302 (2016).

pubmed: 26972336 doi: 10.1016/j.ygyno.2016.03.008

Garris, C. S. et al. Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12. Immunity 49, 1148–1161.e7 (2018).

pubmed: 30552023 pmcid: 6301092 doi: 10.1016/j.immuni.2018.09.024

Dangaj, D. et al. Cooperation between constitutive and inducible chemokines enables T cell engraftment and immune attack in solid tumors. Cancer Cell 35, 885–900.e10 (2019).

pubmed: 31185212 pmcid: 6961655 doi: 10.1016/j.ccell.2019.05.004

Truxova, I. et al. Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients. J. Immunother. Cancer 6, 139 (2018).

pubmed: 30526667 pmcid: 6288908 doi: 10.1186/s40425-018-0446-3

Conejo-Garcia, J. R., Biswas, S., Chaurio, R. & Rodriguez, P. C. Neglected no more: B cell-mediated anti-tumor immunity. Semin. Immunol. 65, 101707 (2023).

pubmed: 36527759 doi: 10.1016/j.smim.2022.101707

Biswas, S. et al. IgA transcytosis and antigen recognition govern ovarian cancer immunity. Nature 591, 464–470 (2021).

pubmed: 33536615 pmcid: 7969354 doi: 10.1038/s41586-020-03144-0

Helmink, B. A. et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577, 549–555 (2020).

pubmed: 31942075 pmcid: 8762581 doi: 10.1038/s41586-019-1922-8

Bruno, T. C. New predictors for immunotherapy responses sharpen our view of the tumour microenvironment. Nature 577, 474–476 (2020).

pubmed: 31965091 pmcid: 7523515 doi: 10.1038/d41586-019-03943-0

Cabrita, R. et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature 577, 561–565 (2020).

pubmed: 31942071 doi: 10.1038/s41586-019-1914-8

Lu, H. et al. Tumor and local lymphoid tissue interaction determines prognosis in high-grade serous ovarian cancer. Cell Rep. Med. 4, 101092 (2023).

pubmed: 37348499 pmcid: 10394173 doi: 10.1016/j.xcrm.2023.101092

Nielsen, J. S. et al. CD20

pubmed: 22553348 doi: 10.1158/1078-0432.CCR-12-0234

Montfort, A. et al. A strong B-cell response is part of the immune landscape in human high-grade serous ovarian metastases. Clin. Cancer Res. 23, 250–262 (2017).

pubmed: 27354470 doi: 10.1158/1078-0432.CCR-16-0081

Sautes-Fridman, C., Petitprez, F., Calderaro, J. & Fridman, W. H. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat. Rev. Cancer 19, 307–325 (2019).

pubmed: 31092904 doi: 10.1038/s41568-019-0144-6

Kasikova, L. et al. Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer. Nat. Commun. 15, 2528 (2024).

pubmed: 38514660 pmcid: 10957872 doi: 10.1038/s41467-024-46873-w

Hwang, W. T., Adams, S. F., Tahirovic, E., Hagemann, I. S. & Coukos, G. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol. Oncol. 124, 192–198 (2012).

pubmed: 22040834 doi: 10.1016/j.ygyno.2011.09.039

Li, X. et al. Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy. J. Pathol. 263, 190–202 (2024).

pubmed: 38525811 doi: 10.1002/path.6274

Shen, J. et al. Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types. J. Immunother. Cancer 12, e008339 (2024).

pubmed: 38355279 pmcid: 10868175 doi: 10.1136/jitc-2023-008339

Roller, A. et al. Tumor-agnostic transcriptome-based classifier identifies spatial infiltration patterns of CD8

pubmed: 38649280 pmcid: 11043740 doi: 10.1136/jitc-2023-008185

Hornburg, M. et al. Single-cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancer. Cancer Cell 39, 928–944.e6 (2021).

pubmed: 33961783 doi: 10.1016/j.ccell.2021.04.004

Desbois, M. et al. Integrated digital pathology and transcriptome analysis identifies molecular mediators of T-cell exclusion in ovarian cancer. Nat. Commun. 11, 5583 (2020).

pubmed: 33149148 pmcid: 7642433 doi: 10.1038/s41467-020-19408-2

Ghisoni, E. et al. Integrated digital pathology and single-cell analysis identify the spatial and temporal evolution of immune cells networks in epithelial ovarian cancer [abstract 27MO]. Ann. Oncol. 33 (Suppl. 5), 395 (2022).

doi: 10.1016/j.annonc.2022.04.045

Hegde, P. S., Karanikas, V. & Evers, S. The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition. Clin. Cancer Res. 22, 1865–1874 (2016).

pubmed: 27084740 doi: 10.1158/1078-0432.CCR-15-1507

Galon, J. et al. Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. J. Pathol. 232, 199–209 (2014).

pubmed: 24122236 doi: 10.1002/path.4287

Fridman, W. H., Zitvogel, L., Sautes-Fridman, C. & Kroemer, G. The immune contexture in cancer prognosis and treatment. Nat. Rev. Clin. Oncol. 14, 717–734 (2017).

pubmed: 28741618 doi: 10.1038/nrclinonc.2017.101

Bruni, D., Angell, H. K. & Galon, J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat. Rev. Cancer 20, 662–680 (2020).

pubmed: 32753728 doi: 10.1038/s41568-020-0285-7

van der Leun, A. M., Thommen, D. S. & Schumacher, T. N. CD8

pubmed: 32024970 pmcid: 7115982 doi: 10.1038/s41568-019-0235-4

Simoni, Y. et al. Bystander CD8

pubmed: 29769722 doi: 10.1038/s41586-018-0130-2

Chen, D. S. & Mellman, I. Elements of cancer immunity and the cancer-immune set point. Nature 541, 321–330 (2017).

pubmed: 28102259 doi: 10.1038/nature21349

Salerno, E. P. et al. Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk. Oncoimmunology 5, e1240857 (2016).

pubmed: 28123876 pmcid: 5215363 doi: 10.1080/2162402X.2016.1240857

Chae, C. S. et al. Tumor-derived lysophosphatidic acid blunts protective type-I interferon responses in ovarian cancer. Cancer Discov. 12, 1904–1921 (2022).

pubmed: 35552618 pmcid: 9357054 doi: 10.1158/2159-8290.CD-21-1181

Song, M. et al. IRE1α-XBP1 controls T cell function in ovarian cancer by regulating mitochondrial activity. Nature 562, 423–428 (2018).

pubmed: 30305738 pmcid: 6237282 doi: 10.1038/s41586-018-0597-x

Barkal, A. A. et al. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature 572, 392–396 (2019).

pubmed: 31367043 pmcid: 6697206 doi: 10.1038/s41586-019-1456-0

Brightwell, R. M. et al. The CD47 “don’t eat me signal” is highly expressed in human ovarian cancer. Gynecol. Oncol. 143, 393–397 (2016).

pubmed: 27569584 pmcid: 5077667 doi: 10.1016/j.ygyno.2016.08.325

Li, H. et al. Dysfunctional CD8 T cells form a proliferative, dynamically regulated compartment within human melanoma. Cell 176, 775–789.e18 (2019).

pubmed: 30595452 doi: 10.1016/j.cell.2018.11.043

Ferrone, S. & Marincola, F. M. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol. Today 16, 487–494 (1995).

pubmed: 7576053 doi: 10.1016/0167-5699(95)80033-6

Han, L. Y. et al. HLA class I antigen processing machinery component expression and intratumoral T-cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin. Cancer Res. 14, 3372–3379 (2008).

pubmed: 18519766 pmcid: 3426216 doi: 10.1158/1078-0432.CCR-07-4433

McPherson, A. et al. Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer. Nat. Genet. 48, 758–767 (2016).

pubmed: 27182968 doi: 10.1038/ng.3573

Zhang, A. W. et al. Interfaces of malignant and immunologic clonal dynamics in ovarian cancer. Cell 173, 1755–1769.e22 (2018).

pubmed: 29754820 doi: 10.1016/j.cell.2018.03.073

Jimenez-Sanchez, A. et al. Heterogeneous tumor-immune microenvironments among differentially growing metastases in an ovarian cancer patient. Cell 170, 927–938.e20 (2017).

pubmed: 28841418 pmcid: 5589211 doi: 10.1016/j.cell.2017.07.025

Launonen, I. M. et al. Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer. Nat. Commun. 13, 835 (2022).

pubmed: 35149709 pmcid: 8837628 doi: 10.1038/s41467-022-28389-3

Ghisoni, E. et al. Myeloid cell networks determine reinstatement of original immune environments in recurrent ovarian cancer. Preprint at bioRxiv https://doi.org/10.1101/2024.05.02.590528 (2024).

Trujillo, J. A., Sweis, R. F., Bao, R. & Luke, J. J. T cell-inflamed versus non-T cell-inflamed tumors: a conceptual framework for cancer immunotherapy drug development and combination therapy selection. Cancer Immunol. Res. 6, 990–1000 (2018).

pubmed: 30181337 pmcid: 6145135 doi: 10.1158/2326-6066.CIR-18-0277

Morad, G., Helmink, B. A., Sharma, P. & Wargo, J. A. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell 185, 576 (2022).

pubmed: 35120665 doi: 10.1016/j.cell.2022.01.008

Kalbasi, A. & Ribas, A. Tumour-intrinsic resistance to immune checkpoint blockade. Nat. Rev. Immunol. 20, 25–39 (2020).

pubmed: 31570880 doi: 10.1038/s41577-019-0218-4

Ghisoni, E., Imbimbo, M., Zimmermann, S. & Valabrega, G. Ovarian cancer immunotherapy: turning up the heat. Int. J. Mol. Sci. 20, 2927 (2019).

pubmed: 31208030 pmcid: 6628106 doi: 10.3390/ijms20122927

Huang, R. Y. et al. LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8

pubmed: 26318293 pmcid: 4694995 doi: 10.18632/oncotarget.4751

Fucikova, J. et al. TIM-3 dictates functional orientation of the immune infiltrate in ovarian cancer. Clin. Cancer Res. 25, 4820–4831 (2019).

pubmed: 31076549 doi: 10.1158/1078-0432.CCR-18-4175

Blanc-Durand, F. et al. Distribution of novel immune-checkpoint targets in ovarian cancer tumor microenvironment: a dynamic landscape. Gynecol. Oncol. 160, 279–284 (2021).

pubmed: 33162175 doi: 10.1016/j.ygyno.2020.09.045

Schöffski, P. et al. Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. J. Immunother. Cancer 10, e003776 (2022).

pubmed: 35217575 pmcid: 8883259 doi: 10.1136/jitc-2021-003776

Harding, J. J. et al. Blocking TIM-3 in treatment-refractory advanced solid tumors: a phase Ia/b study of LY3321367 with or without an anti-PD-L1 antibody. Clin. Cancer Res. 27, 2168–2178 (2021).

pubmed: 33514524 doi: 10.1158/1078-0432.CCR-20-4405

Curigliano, G. et al. Phase I/Ib clinical trial of sabatolimab, an anti-TIM-3 antibody, alone and in combination with spartalizumab, an anti-PD-1 antibody, in advanced solid tumors. Clin. Cancer Res. 27, 3620–3629 (2021).

pubmed: 33883177 doi: 10.1158/1078-0432.CCR-20-4746

Sanborn, R. E. et al. Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors. J. Immunother. Cancer 10, e005147 (2022).

pubmed: 35940825 pmcid: 9364417 doi: 10.1136/jitc-2022-005147

Mascarelli, D. E. et al. Boosting antitumor response by costimulatory strategies driven to 4-1BB and OX40 T-cell receptors. Front. Cell Dev. Biol. 9, 692982 (2021).

pubmed: 34277638 pmcid: 8277962 doi: 10.3389/fcell.2021.692982

Ramser, M. et al. High OX40 expression in recurrent ovarian carcinoma is indicative for response to repeated chemotherapy. BMC Cancer 18, 425 (2018).

pubmed: 29661166 pmcid: 5903007 doi: 10.1186/s12885-018-4339-0

Moiseyenko, A. et al. Sequential therapy with INCAGN01949 followed by ipilimumab and nivolumab in two patients with advanced ovarian carcinoma. Gynecol. Oncol. Rep. 34, 100655 (2020).

pubmed: 33083509 pmcid: 7554352 doi: 10.1016/j.gore.2020.100655

Goldman, J. W. et al. Safety and tolerability of MEDI0562, an OX40 agonist mAb, in combination with durvalumab or tremelimumab in adult patients with advanced solid tumors. Clin. Cancer Res. 28, 3709–3719 (2022).

pubmed: 35699623 doi: 10.1158/1078-0432.CCR-21-3016

Hoffman-Censits, J. et al. The JAVELIN Bladder Medley trial: avelumab-based combinations as first-line maintenance in advanced urothelial carcinoma. Future Oncol. 20, 179–190 (2024).

pubmed: 37671748 doi: 10.2217/fon-2023-0492

Hui, E. et al. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science 355, 1428–1433 (2017).

pubmed: 28280247 pmcid: 6286077 doi: 10.1126/science.aaf1292

Kamphorst, A. O. et al. Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. Science 355, 1423–1427 (2017).

pubmed: 28280249 pmcid: 5595217 doi: 10.1126/science.aaf0683

Lakhani, N. et al. Phase 1 dose escalation study of the agonist redirected checkpoint, SL-172154 (SIRPα-Fc-CD40L) in subjects with platinum-resistant ovarian cancer [abstract 429]. J. Immunother. Cancer 9 (Suppl. 2), A459 (2021).

Frankish, J. et al. The CD40 agonist HERA-CD40L results in enhanced activation of antigen presenting cells, promoting an anti-tumor effect alone and in combination with radiotherapy. Front. Immunol. 14, 1160116 (2023).

pubmed: 37304285 pmcid: 10251205 doi: 10.3389/fimmu.2023.1160116

Ochoa de Olza, M., Navarro Rodrigo, B., Zimmermann, S. & Coukos, G. Turning up the heat on non-immunoreactive tumours: opportunities for clinical development. Lancet Oncol. 21, e419–e430 (2020).

pubmed: 32888471 doi: 10.1016/S1470-2045(20)30234-5

Galon, J. & Bruni, D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat. Rev. Drug. Discov. 18, 197–218 (2019).

pubmed: 30610226 doi: 10.1038/s41573-018-0007-y

Wang, M., Wang, S., Desai, J., Trapani, J. A. & Neeson, P. J. Therapeutic strategies to remodel immunologically cold tumors. Clin. Transl. Immunol. 9, e1226 (2020).

doi: 10.1002/cti2.1226

Herrera, F. G. et al. Low-dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy. Cancer Discov. 12, 108–133 (2022).

pubmed: 34479871 doi: 10.1158/2159-8290.CD-21-0003

Zamarin, D. et al. Study to evaluate intraperitoneal (IP) ONCOS-102 with systemic durvalumab in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC): phase 2 results [abstract]. J. Clin. Oncol. 40 (Suppl. 16), 2600 (2022).

doi: 10.1200/JCO.2022.40.16_suppl.2600

Barsoumian, H. B. et al. Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma. J. Immunother. Cancer 8, e000537 (2020).

pubmed: 33106386 pmcid: 7592253 doi: 10.1136/jitc-2020-000537

Reislander, T., Groelly, F. J. & Tarsounas, M. DNA damage and cancer immunotherapy: a STING in the tale. Mol. Cell 80, 21–28 (2020).

pubmed: 32810436 doi: 10.1016/j.molcel.2020.07.026

Xu, H. et al. CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models. Cell Rep. Med. 2, 100394 (2021).

pubmed: 34622231 pmcid: 8484689 doi: 10.1016/j.xcrm.2021.100394

Keenan, T. E. et al. Clinical efficacy and molecular response correlates of the WEE1 inhibitor adavosertib combined with cisplatin in patients with metastatic triple-negative breast cancer. Clin. Cancer Res. 27, 983–991 (2021).

pubmed: 33257427 doi: 10.1158/1078-0432.CCR-20-3089

Binnewies, M. et al. Targeting TREM2 on tumor-associated macrophages enhances immunotherapy. Cell Rep. 37, 109844 (2021).

pubmed: 34686340 doi: 10.1016/j.celrep.2021.109844

MacGregor, H. L. et al. High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation. J. Immunother. Cancer 7, 357 (2019).

pubmed: 31892360 pmcid: 6937725 doi: 10.1186/s40425-019-0816-5

Beckermann, K. E. et al. A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma. Invest. New Drugs 42, 179–184 (2024).

pubmed: 38372949 doi: 10.1007/s10637-024-01419-1

Curiel, T. J. et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10, 942–949 (2004).

pubmed: 15322536 doi: 10.1038/nm1093

DePeaux, K. & Delgoffe, G. M. Metabolic barriers to cancer immunotherapy. Nat. Rev. Immunol. 21, 785–797 (2021).

pubmed: 33927375 pmcid: 8553800 doi: 10.1038/s41577-021-00541-y

Morotti, M. et al. PGE2 inhibits TIL expansion by disrupting IL-2 signalling and mitochondrial function. Nature 629, 426–434 (2024).

pubmed: 38658764 pmcid: 11078736 doi: 10.1038/s41586-024-07352-w

Eynde, B. J. V. D., Baren, N. V. & Baurain, J.-F. Is there a clinical future for IDO1 inhibitors after the failure of epacadostat in melanoma? Annu. Rev. Cancer Biol. 4, 241–256 (2020).

doi: 10.1146/annurev-cancerbio-030419-033635

An, D., Banerjee, S. & Lee, J. M. Recent advancements of antiangiogenic combination therapies in ovarian cancer. Cancer Treat. Rev. 98, 102224 (2021).

pubmed: 34051628 pmcid: 8217312 doi: 10.1016/j.ctrv.2021.102224

Huinen, Z. R., Huijbers, E. J. M., van Beijnum, J. R., Nowak-Sliwinska, P. & Griffioen, A. W. Anti-angiogenic agents – overcoming tumour endothelial cell anergy and improving immunotherapy outcomes. Nat. Rev. Clin. Oncol. 18, 527–540 (2021).

pubmed: 33833434 doi: 10.1038/s41571-021-00496-y

Lacher, S. B. et al. PGE

pubmed: 38658748 pmcid: 11078747 doi: 10.1038/s41586-024-07254-x

Rutten, M. J. et al. Laparoscopy to predict the result of primary cytoreductive surgery in patients with advanced ovarian cancer: a randomized controlled trial. J. Clin. Oncol. 35, 613–621 (2017).

pubmed: 28029317 doi: 10.1200/JCO.2016.69.2962

Topalian, S. L. et al. Neoadjuvant immune checkpoint blockade: a window of opportunity to advance cancer immunotherapy. Cancer Cell 41, 1551–1566 (2023).

pubmed: 37595586 doi: 10.1016/j.ccell.2023.07.011

Porter, R. L. et al. A phase 2, two-stage study of mirvetuximab soravtansine (IMGN853) in combination with pembrolizumab in patients with microsatellite stable (MSS) recurrent or persistent endometrial cancer [abstract]. Cancer Res. 84 (Suppl. 7), CT008 (2024).

doi: 10.1158/1538-7445.AM2024-CT008

Lybaert, L. et al. Challenges in neoantigen-directed therapeutics. Cancer Cell 41, 15–40 (2023).

pubmed: 36368320 doi: 10.1016/j.ccell.2022.10.013

Zacharakis, N. et al. Breast cancers are immunogenic: immunologic analyses and a phase II pilot clinical trial using mutation-reactive autologous lymphocytes. J. Clin. Oncol. 40, 1741–1754 (2022).

pubmed: 35104158 pmcid: 9148699 doi: 10.1200/JCO.21.02170

Schmidt, J. et al. Neoantigen-specific CD8 T cells with high structural avidity preferentially reside in and eliminate tumors. Nat. Commun. 14, 3188 (2023).

pubmed: 37280206 pmcid: 10244384 doi: 10.1038/s41467-023-38946-z

Kast, F., Klein, C., Umana, P., Gros, A. & Gasser, S. Advances in identification and selection of personalized neoantigen/T-cell pairs for autologous adoptive T cell therapies. Oncoimmunology 10, 1869389 (2021).

pubmed: 33520408 pmcid: 7808433 doi: 10.1080/2162402X.2020.1869389

Kandalaft, L. E., Odunsi, K. & Coukos, G. Immunotherapy in ovarian cancer: are we there yet? J. Clin. Oncol. 37, 2460–2471 (2019).

pubmed: 31403857 doi: 10.1200/JCO.19.00508

Dafni, U. et al. Efficacy of cancer vaccines in selected gynaecological breast and ovarian cancers: a 20-year systematic review and meta-analysis. Eur. J. Cancer 142, 63–82 (2021).

pubmed: 33221598 doi: 10.1016/j.ejca.2020.10.014

Harari, A., Graciotti, M., Bassani-Sternberg, M. & Kandalaft, L. E. Antitumour dendritic cell vaccination in a priming and boosting approach. Nat. Rev. Drug. Discov. 19, 635–652 (2020).

pubmed: 32764681 doi: 10.1038/s41573-020-0074-8

Tanyi, J. L. et al. Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. Sci. Transl. Med. 10, eaao5931 (2018).

pubmed: 29643231 doi: 10.1126/scitranslmed.aao5931

Kandalaft, L. E. et al. Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. Oncoimmunology 2, e22664 (2013).

pubmed: 23482679 pmcid: 3583933 doi: 10.4161/onci.22664

Bobisse, S. et al. A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer. Nat. Cancer 4, 1410–1417 (2023).

pubmed: 37735588 doi: 10.1038/s43018-023-00623-x

Atsavapranee, E. S., Billingsley, M. M. & Mitchell, M. J. Delivery technologies for T cell gene editing: applications in cancer immunotherapy. EBioMedicine 67, 103354 (2021).

pubmed: 33910123 pmcid: 8099660 doi: 10.1016/j.ebiom.2021.103354

Corria-Osorio, J. et al. Orthogonal cytokine engineering enables novel synthetic effector states escaping canonical exhaustion in tumor-rejecting CD8

pubmed: 37081150 pmcid: 10154250 doi: 10.1038/s41590-023-01477-2

Vlad, A. M. et al. A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer. Cancer Immunol. Immunother. 59, 293–301 (2010).

pubmed: 19690855 doi: 10.1007/s00262-009-0750-3

Mucci, A. et al. Myeloid cell-based delivery of IFN-γ reprograms the leukemia microenvironment and induces anti-tumoral immune responses. EMBO Mol. Med. 13, e13598 (2021).

pubmed: 34459560 pmcid: 8495462 doi: 10.15252/emmm.202013598

Escobar, G. et al. Genetic engineering of hematopoiesis for targeted IFN-α delivery inhibits breast cancer progression. Sci. Transl. Med. 6, 217ra213 (2014).

doi: 10.1126/scitranslmed.3006353

Bertucci, F. et al. High-dose melphalan-based chemotherapy and autologous stem cell transplantation after second look laparotomy in patients with chemosensitive advanced ovarian carcinoma: long-term results. Bone Marrow Transpl. 26, 61–67 (2000).

doi: 10.1038/sj.bmt.1702468

Sabatier, R. et al. Are there candidates for high-dose chemotherapy in ovarian carcinoma? J. Exp. Clin. Cancer Res. 31, 87 (2012).

pubmed: 23072336 pmcid: 3523074 doi: 10.1186/1756-9966-31-87

Muller, A. M. et al. Long-term outcome of patients with metastatic breast cancer treated with high-dose chemotherapy and transplantation of purified autologous hematopoietic stem cells. Biol. Blood Marrow Transpl. 18, 125–133 (2012).

doi: 10.1016/j.bbmt.2011.07.009

Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach.

Journal

Informations de publication

Résumé

Identifiants

Types de publication

Langues

Sous-ensembles de citation

Informations de copyright

Références

Auteurs

Eleonora Ghisoni (E)

Matteo Morotti (M)

Apostolos Sarivalasis (A)

Alizée J Grimm (AJ)

Lana Kandalaft (L)

Denarda Dangaj Laniti (DD)

George Coukos (G)

Classifications MeSH